Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis

Cerivastatin, an HMG-CoA reductase inhibitor withdrawn from the market due to serious adverse effects, is metabolized primarily by CYP2C8. The occurrence of associated myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics due to gemfibrozil-inhibition or genetic var...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Kaspera, Rüdiger, Naraharisetti, Suresh B., Tamraz, Bani, Sahele, Tariku, Cheesman, Matthew J., Kwok, Pui-Yan, Marciante, Kristin, Heckbert, Susan R., Psaty, Bruce M., Totah, Rheem A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993694/
https://ncbi.nlm.nih.gov/pubmed/20739906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0b013e32833ecace
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items